Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

The Lancet. Haematology·2026
Same author

From Molecular Complexity to Personalized Care in Chronic Myelomonocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

Leukemia·2026
Same author

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study.

Cancer science·2026
Same author

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation·2026
Same author

Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators.

Science advances·2026
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

End of headings.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
Same journal

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

Donor cell leukemia: a review.

Daniel H Wiseman1

  • 1Haematology Department, Manchester Royal Infirmary, Manchester, United Kingdom. daniel.wiseman@cmft.nhs.uk

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|October 19, 2010
PubMed
Summary
This summary is machine-generated.

Donor cell leukemia (DCL) is a rare form of acute leukemia developing in transplanted cells. Recent data suggest DCL may account for up to 5% of post-transplant leukemia relapses, necessitating careful diagnostic evaluation.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: Jun 8, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Relapse of acute leukemia post-hematopoietic stem cell transplantation (HSCT) is typically a recurrence of the patient's original leukemia.
  • Donor cell leukemia (DCL) is a rare condition where acute leukemia develops de novo from the donor's engrafted cells.
  • Advances in molecular chimerism monitoring suggest DCL may be more prevalent than previously thought, potentially up to 5% of post-HSCT leukemia relapses.

Purpose of the Study:

  • To review and collate reported cases of DCL.
  • To discuss diagnostic strategies, controversies, and challenges in determining the origin of post-transplant leukemia.
  • To explore potential etiologic factors, mechanisms of leukemogenesis, and ethical considerations of DCL.

Main Methods:

  • Literature review and collation of all reported DCL cases.
  • Analysis of diagnostic approaches for distinguishing recipient-derived relapse from DCL.
  • Discussion of molecular monitoring techniques and their role in DCL identification.

Main Results:

  • DCL, though historically considered rare, is increasingly recognized, possibly representing up to 5% of post-HSCT leukemia relapses.
  • Distinguishing DCL from recipient-derived relapse is critical for appropriate therapeutic strategies, as graft-versus-leukemia effects differ.
  • DCL has significant implications for donor health, selection, and ethical considerations regarding donor notification.

Conclusions:

  • DCL is an important entity to recognize in post-HSCT leukemia, with implications for treatment and donor management.
  • Further research into DCL mechanisms may provide insights into leukemogenesis.
  • Ethical frameworks are needed to address the complexities arising from donor-derived malignancies.